Evolus, Inc.
HealthcareNASDAQ:EOLS · NASDAQ Global Market
+$0.22 today
Vol 0.63M · Avg 0.87M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
223.5%
avg -61.2%
ROIC
-24.6%
avg -37.3%
ROA
-22.9%
avg -31.5%
Analysis
ROE is currently the strongest return metric at 223.5% versus its period average of -61.2%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
David Moatazedi | President, Chief Executive Officer & Director | $1.23M | — | 48 | $604,700.00 | 0.92% |
Rui Avelar C.CFP Dip.SportMed | Chief Medical Officer and Head of Research & Development | $730,167.00 | — | 64 | $427,423.00 | 0.65% |
Tatjana Mitchell | Chief Financial Officer | $711,398.00 | — | — | $226,092.00 | 0.34% |
Tomoko Yamagishi-Dressler | Chief Marketing Officer | $677,374.00 | — | 61 | $89,949.00 | 0.14% |
Nareg Sagherian | Head of Global Investor Relations & Corporate Communications | — | — | — | — | — |
Kurt Knab | Senior Vice President of Sales | — | — | — | — | — |
Jeffrey J. Plumer | Corporate Secretary | — | — | — | — | — |
Jessica Novak | Senior Vice President of Human Resources | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$204,486.00
Sells
9
$2.21M
Net Sentiment
$2.01M
Net selling
Most Active
MOATAZEDI DAVID
5 transactions
Analysis
Insiders reported 1 buys worth $204,486.00 and 9 sells worth $2.21M over the last 12 months. That adds up to net selling of $2.01M. MOATAZEDI DAVID was the most active insider with 5 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | +29.3% (11yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Forward estimates point to Revenue at +29.3% (11yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Enhabit, Inc.
EHAB
$706.91M
CeriBell, Inc.
NASDAQ:CBLL
$700.80M
Solid Biosciences Inc.
NASDAQ:SLDB
$556.28M
The Oncology Institute, Inc.
NASDAQ:TOI
$530.91M
Neurogene Inc.
NASDAQ:NGNE
$459.84M
OrthoPediatrics Corp.
NASDAQ:KIDS
$457.71M
Kamada Ltd.
NASDAQ:KMDA
$429.18M
Autolus Therapeutics plc
NASDAQ:AUTL
$415.18M
Treace Medical Concepts, Inc.
NASDAQ:TMCI
$263.38M
Quantum-Si incorporated
NASDAQ:QSI
$187.28M
Who manages EOLS?
Evolus, Inc. (EOLS) lists 8 active executives. The top listed executive is David Moatazedi, President, Chief Executive Officer & Director.
Are EOLS insiders buying or selling?
Recent insider activity shows net selling of $49.59M.
Explore More
Continue the stock analysis
Jump to another research area for this company.